Table 3.
Changes following subcutaneous infusion of apomorphine in patients with Parkinson’s disease (n = 51).
| Time period | Baseline | Month 6 | pa | Month 12 | pb | pc |
|---|---|---|---|---|---|---|
| Measure | Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | |||
| Dose of medication | ||||||
| LEDD | 823.73 ± 267.17 (400–1800) | 574.51 ± 169.52 (200–1000) | < 0.001 | 407.84 ± 132.43 (200–800) | < 0.001 | < 0.001 |
| Apomorphine | – | 24.67 ± 4.19 (18–36) | – | 36.00 ± 6.79 (24–60) | – | < 0.001 |
| UPDRS | ||||||
| Part 2d | 30.18 ± 1.85 (27–33) | 23.41 ± 2.30 (19–27) | < 0.001 | – | ||
| Part 3 | 46.78 ± 4.21 (39–57) | 34.96 ± 2.03 (30–39) | < 0.001 | 34.43 ± 0.86 (33–36) | < 0.001 | n.s. |
| Part 4 | 17.78 ± 2.33 (13–22) | 14.02 ± 1.42 (12–18) | < 0.001 | 11.98 ± 1.52 (9–15) | < 0.001 | < 0.001 |
| NMSS totale | 128.06 ± 18.33 (87–161) | 95.51 ± 100.0 (68–118) | < 0.001 | 78.00 ± 21.32 (46–124) | < 0.001 | < 0.001 |
| PDQ-8 Summary index | 59.56 ± 7.45 (43.75–75.0) | 42.50 ± 5.54 (37.5–53.13) | < 0.001 | 43.75 ± 5.56 (37.5–53.13) | < 0.001 | n.s. |
| HADS-Depression | 12.22 ± 2.06 (8–18) | 10.51 ± 1.43 (6–14) | < 0.001 | 10.51 ± 1.43 (6–14) | < 0.001 | n.s. |
| HADS-Anxiety | 13.02 ± 7.75 (9–18) | 10.31 ± 1.53 (6–14) | < 0.001 | 10.51 ± 1.43 (6–14) | < 0.001 | n.s. |
| MOCA | 24.55 ± 2.77 (20–30) | 24.55 ± 2.77 (20–30) | n.s. | 24.59 ± 2.66 (20–30) | n.s. | n.s. |
| PFS-16 | 11.16 ± 3.66 (0–16) | 9.33 ± 2.78 (0–12) | < 0.001 | 9.82 ± 3.03 (0–16) | < 0.001 | n.s. |
| PDSS | 63.55 ± 18.07 (20–90) | 66.18 ± 12.63 (30–90) | n.s. | 66.18 ± 12.36 (30–90) | n.s. | n.s. |
| KPPS | 40.59 ± 8.56 (21–67) | 33.69 ± 9.10 (20–60) | < 0.001 | 33.29 ± 9.23 (20–60) | < 0.001 | n.s. |
aWilcoxon test for baseline vs month 6 scores; bWilcoxon test for baseline vs month 12 scores; cWilcoxon test for month 6 vs month 12 scores; dSD Standard deviation, LEDD Levodopa equivalent daily dose, UPDRS Unified Parkinson’s disease rating scale, NMSS non motor symptoms scale, PDQ-8 8-item Parkinson's disease questionnaire, HADS hospital anxiety and depression scale, MOCA Montreal cognitive assessment, PFS-16 Parkinson’s disease fatigue scale, PDSS Parkinson’s disease sleep scale, KPPS King’s PD Pain Scale.